About Immunovant (IMVT)
Immunovant, Inc., formerly Health Sciences Acquisitions Corp, is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. It is developing IMVT-1401, a human anti-FcRn monoclon... Read more
- USD28.21
- USD28.52
- USD27.44
- USD45.58
- -10.60%
- --
- 1.27M
- 1.04M
- 4.1B
- 15.90
- 80.70%
Stock News
yesterday
Cramer praises companies like Chipotle that can grow despite a slowing economy and inflation
CNBC
yesterday
Bristol Myers Squibb stock tumbles on cost-cutting initiative
Yahoo
yesterday
Alphabet stock pops off on Q1 earnings beat, cash dividend
Yahoo
yesterday
H&R Block to Release Fiscal 2024 Third Quarter Results on May 9, 2024
Yahoo
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
